- Poster presentation
- Open access
- Published:
Risk factors for non-vancomycin-resistant enterococcus faecium infection
Intensive Care Medicine Experimental volume 3, Article number: A124 (2015)
Introduction
Enterococci spp. cause serious infections in ICU environment. Among them, Enterococcus faecium may constitute a problem when choosing empirical treatment. In addition, vancomycin-resistant Enterococci is growing as an epidemiological problem.
Objectives
To identify risk factors for acquisition of an E. Faecium infection in patients admitted to Intensive Care Unit (ICU).
Methods
We analyzed retrospective data from patients admitted to a polivalent ICU during a 4-year period. We specifically analyzed those patients with an infection during their ICU stay and search for factors related to the isolation of E. faecium from clinical samples.
Results
We studied 841 patients, 21 of them (2.5 %) with an E. Faecium infection. No E. faecium vancomycin resistance was found.
Patients with E. Faecium isolation were older (69.5 vs 64), infections had been acquired in the hospital, were surgical patients in higher proportion and had longer ICU stay (81 vs 44.3 % p 0.001 and 57.1 vs 27.5 % p 0.003 and 6 (3-11) vs 13 (6-25) p 0.001 respectively), had received parenteral nutrition (43 v 13 % p 0.001) and were malnourished in higher rate (25 v 4.2 % p 0.001) Prior use of piperacilina-tazobactam, carbapenem or linezolid were found more frequently in E. Faecium-infected patients (52.4 vs 24.1 % p 0.003 and 66.7 vs 20.6 % p 0.001) ESBL isolation coexisted more frequently in patients with E. Faecium infection. Mortality rate was higher in patients with E. faecium infection (57 vs 25.6 % p 0.001).
Logistic regression analysis showed nosocomial admission, prior use of piperaciline-tazobactam or carbapenem and ESBL isolation as independent risk factors for E. faecium infection. E. faecium infection was not independently associated with mortality.
Conclusions
Non-community admissions and prior exposure to piperaciline-tazobactam and carbapenem resulted being associated with isolation of E. faecium in our patients.
ESBL isolation appeared independently associated with E. faecium, probably because both bacteria share ways of selection. Controlling raising incidence of E. faecium may prevent vancomycin-resistant Enterococci spread, not still a problem in our environment.
References
Humphreys H: J Hosp Infect. 2014, 88 (4): 191-8. 10.1016/j.jhin.2014.09.002. Dec
Alvarez Lerma F: Med Clin (Barc). 2003, 121 (8): 281-6. 10.1016/S0025-7753(03)73919-0.
Jung E: Am J Infect Control. 2014, 42 (10): 1062-6. 10.1016/j.ajic.2014.06.024. Oct
Sung-Chin P: PLoS ONE. 7 (10): e47297-
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Jiménez, R., Ortín, A., Rebollo, S. et al. Risk factors for non-vancomycin-resistant enterococcus faecium infection. ICMx 3 (Suppl 1), A124 (2015). https://doi.org/10.1186/2197-425X-3-S1-A124
Published:
DOI: https://doi.org/10.1186/2197-425X-3-S1-A124